



ASX ANNOUNCEMENT

19 December 2023

## REVISED TIMETABLE FOR PROSPECTUS

*Not for release to US wire services or distribution in the United States*

CardieX Limited (ASX: CDX) (**CardieX**, the **Company**) wish to provide a revised timetable for the Prospectus released to the ASX on 19 December 2023.

### Indicative Timetable

Event	Date
Lodgement of Prospectus with ASIC Lodgement of Prospectus, announcement of Offers and lodgement of Appendix 3B with ASX Opening date for Shortfall Offer	Tuesday, 19 December 2023
Ex date	Thursday, 21 December 2023
Record Date for determining Entitlements under the Entitlement Offer	Friday, 22 December 2023
Issue of Shares under Tranche 1 of the Share Placement*	Wednesday, 27 December 2023
Prospectus and Application Forms made available to Eligible Shareholders Opening date of Entitlement Offer Opening date for Share Placement Offer, Lead Manager Offer and Convertible Note Offer	Friday, 29 December 2023
Last day to extend Closing Date of Entitlement Offer (before noon)	Monday, 29 January 2024
Closing Date of Entitlement Offer, Share Placement Offer, Lead Manager Offer and Convertible Note Offer (5:00pm AEDT) Anticipated date for General Meeting of Shareholders	Thursday, 1 February 2024
New Securities quoted on a deferred settlement basis	Friday, 2 February 2024
Announcement of results of the Entitlement Offer Anticipated date for issue of Shares under Tranche 2 of the Share Placement (including to related parties)* Anticipated date for issue of Shares on conversion of Convertible Notes	Tuesday, 6 February 2024

For personal use only



Event	Date
Anticipated date for issue of the New Securities under the Entitlement Offer Anticipated date for issue of the Quoted Options under the Share Placement Offer, Lead Manager Offer and Convertible Note Offer	Wednesday, 7 February 2024
Anticipated date for commencement of New Securities trading on a normal settlement basis	Thursday, 8 February 2024
Shortfall Offer Closing Date	Wednesday, 1 May 2024

*\* Completion of the Placement is conditional on ASX agreeing to lift the Company's suspension from quotation. Completion of Tranche 2 of the Placement is also conditional on shareholder approval at the General Meeting.*

*The above dates are indicative only and may change without notice. The Company reserves the right to vary any and all of the above dates without notice, subject to the Corporations Act, Listing Rules and other applicable laws. In particular, the Company reserves the right to vary the opening date of any offer and the closing date of any offer without prior notice, which may have a consequential effect on the other dates. The Company also reserves the right not to proceed with the offers at any time before the issue of New Shares and Quoted Options. The Shortfall Offer may close at such earlier date as the Directors, in their absolute discretion, determine.*

**Approved by the Board of Directors and Released by the Company Secretary**

**- ENDS -**

For more information, please contact:

**Investor Relations**

Rod Hinchcliffe  
rod.hinchcliffe@mcpartners.com.au

**Media Relations**

Melissa Hamilton  
melissa.hamilton@mcpartners.com.au

**Investor Relations – USA**

Matt Selinger  
Managing Director, Integrous Communications  
mselinger@integcom.com

**About CardieX**

CardieX is a medical technology company that develops and markets non-invasive patient monitoring technologies for assessing vascular health. The Company's suite of products includes medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders - all based on the Company's market leading SphygmoCor® vascular biomarker technology. CardieX is listed on the Australian Stock Exchange ("CDX").

For personal use only



## Important Notice

### Not for distribution or release in the United States

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States or any other jurisdiction in which such an offer would be illegal. Any securities described in this announcement have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended ("**US Securities Act**") or the securities laws of any other state or other jurisdiction of the United States. Accordingly, the securities described in this announcement may not be offered or sold, directly or indirectly, in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable laws of any state or other jurisdiction of the United States.

### Forward-Looking Statements

This announcement contains certain contains certain "forward-looking statements". The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this announcement are based on assumptions and contingencies that are subject to change without notice and involve known and unknown risks and uncertainties and other factors that are beyond the control of CardieX, its directors and management. This includes statements about market and industry trends, which are based on interpretations of current market conditions.

Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any projections and assumptions on which these statements are based. These statements may assume the success of CardieX's business strategies. The success of any of those strategies will be realised in the period for which the forward-looking statement may have been prepared or otherwise. Readers are cautioned not to place undue reliance on forward-looking statements and except as required by law or regulation, none of CardieX, its representatives or advisers assumes any obligation to update these forward-looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this announcement. The forward-looking statements are based on information available to CardieX as at the date of this announcement. Except as required by law or regulation (including the Listing Rules), none of CardieX, its representatives or advisers undertakes any obligation to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements.

For personal use only